Business Description
Edwards Lifesciences Corp
NAICS : 339113
SIC : 3842
ISIN : US28176E1082
Share Class Description:
MEX:EW: Ordinary SharesCompare
Compare
Traded in other countries / regions
EW.USAEW.MexicoEWL.Germany1EW.ItalyE1WL34.BrazilEWLS.Austria0REN.UK IPO Date
2017-10-18Description
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.37 | |||||
| Equity-to-Asset | 0.71 | |||||
| Debt-to-Equity | 0.1 | |||||
| Debt-to-EBITDA | 0.4 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 15.02 | |||||
| Beneish M-Score | -1.99 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 12.4 | |||||
| 3-Year EBITDA Growth Rate | 20.6 | |||||
| 3-Year EPS without NRI Growth Rate | 11 | |||||
| 3-Year FCF Growth Rate | 0.3 | |||||
| 3-Year Book Growth Rate | 14.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 9.34 | |||||
| Future 3-5Y Total Revenue Growth Rate | 10.75 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 6.97 | |||||
| 9-Day RSI | 29.8 | |||||
| 14-Day RSI | 48.6 | |||||
| 6-1 Month Momentum % | 31.2 | |||||
| 12-1 Month Momentum % | 0.31 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.38 | |||||
| Quick Ratio | 2.4 | |||||
| Cash Ratio | 1.38 | |||||
| Days Inventory | 262.98 | |||||
| Days Sales Outstanding | 44.13 | |||||
| Days Payable | 51.2 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 1.3 | |||||
| Shareholder Yield % | 1.65 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 77.02 | |||||
| Operating Margin % | 28.81 | |||||
| Net Margin % | 23.36 | |||||
| FCF Margin % | 10.61 | |||||
| ROE % | 22.28 | |||||
| ROA % | 15.69 | |||||
| ROIC % | 22.75 | |||||
| ROC (Joel Greenblatt) % | 59.57 | |||||
| ROCE % | 20.72 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 38.53 | |||||
| Forward PE Ratio | 33.11 | |||||
| PE Ratio without NRI | 35.37 | |||||
| Shiller PE Ratio | 51.16 | |||||
| Price-to-Owner-Earnings | 107.93 | |||||
| PEG Ratio | 2.01 | |||||
| PS Ratio | 8.99 | |||||
| PB Ratio | 8.01 | |||||
| Price-to-Tangible-Book | 10.71 | |||||
| Price-to-Free-Cash-Flow | 85.86 | |||||
| Price-to-Operating-Cash-Flow | 60.32 | |||||
| EV-to-EBIT | 32.42 | |||||
| EV-to-Forward-EBIT | 27.5 | |||||
| EV-to-EBITDA | 29.76 | |||||
| EV-to-Forward-EBITDA | 24.93 | |||||
| EV-to-Revenue | 8.72 | |||||
| EV-to-Forward-Revenue | 8.05 | |||||
| EV-to-FCF | 83.22 | |||||
| Price-to-Projected-FCF | 2.91 | |||||
| Price-to-DCF (Earnings Based) | 1.16 | |||||
| Price-to-DCF (FCF Based) | 6.19 | |||||
| Price-to-Median-PS-Value | 1 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.83 | |||||
| Price-to-Graham-Number | 4.11 | |||||
| Price-to-Net-Current-Asset-Value | 40.28 | |||||
| Earnings Yield (Greenblatt) % | 3.08 | |||||
| FCF Yield % | 1.18 | |||||
| Forward Rate of Return (Yacktman) % | 20.93 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Edwards Lifesciences Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 105,227.408 | ||
| EPS (TTM) (MXN) | 40.309 | ||
| Beta | -0.06 | ||
| Volatility % | 31.75 | ||
| 14-Day RSI | 48.6 | ||
| 14-Day ATR (MXN) | 2.729497 | ||
| 20-Day SMA (MXN) | 1546.5525 | ||
| 12-1 Month Momentum % | 0.31 | ||
| 52-Week Range (MXN) | 1132.99 - 1614.99 | ||
| Shares Outstanding (Mil) | 601.93 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Edwards Lifesciences Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Edwards Lifesciences Corp Stock Events
| Event | Date | Price(MXN) | ||
|---|---|---|---|---|
| No Event Data | ||||
Edwards Lifesciences Corp Frequently Asked Questions
What is Edwards Lifesciences Corp(MEX:EW)'s stock price today?
The current price of MEX:EW is MXN1538.57. The 52 week high of MEX:EW is MXN1614.99 and 52 week low is MXN1132.99.
When is next earnings date of Edwards Lifesciences Corp(MEX:EW)?
The next earnings date of Edwards Lifesciences Corp(MEX:EW) is 2024-04-25.
Does Edwards Lifesciences Corp(MEX:EW) pay dividends? If so, how much?
Edwards Lifesciences Corp(MEX:EW) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers